Transanal endoscopic operation for rectal cancer after neoadjuvant therapy
AUTOR(ES)
Rocha, José Joaquim Ribeiro da, Bernardes, Mário Vinícius Angelete Alvarez, Feitosa, Marley Ribeiro, Perazzoli, Camila, Machado, Vanessa Foresto, Peria, Fernanda Maris, Oliveira, Harley Francisco de, Feres, Omar
FONTE
Acta Cir. Bras.
DATA DE PUBLICAÇÃO
2016
RESUMO
PURPOSE: In this paper we report the oncological outcomes from clinical series of patients with rectal cancer submitted to local excision after neoadjuvant therapy and discuss the indications for local excision in partial clinical responders. METHODS: We analysed a prospective database of 39 patients submitted to a transanal endoscopic operation for rectal cancer after neoadjuvant chemoradiation between 2006 and 2015, comparing clinical and pathological variables, perioperative complications, recurrence rate and overall survival. RESULTS: We obtained 15.4% ypT0, 17.9% ypT1, 35.9% ypT2 and 28.2% ypT3. After a median follow-up of 24 months, tumoral recurrence was observed in 4 patients, one of them with isolated pulmonary metastasis. R0 resection was achieved in 79.5%, and postoperative complications were observed in 30.2% patients and no perioperative mortality occur. Compromise surgical margins do not affect recurrence rate, and 94.9% of patients are alive nowadays. CONCLUSION: Local excision could be associated with low recurrence rate and good overall survival. Short hospitalization time and low level of serious complications observed could be an interesting option for patients who would not tolerate a radical procedure or for those who declined a total mesorectal excision. A strict long-term follow-up must be warranted to detect early tumoral recurrence.
Documentos Relacionados
- Timing of neoadjuvant therapy and surgical treatment in rectal cancer
- A Way to Start Transanal Total Mesorectal Excision for Rectal Cancer
- STUDY OF ANORECTAL PHYSIOLOGY PRE AND POS NEOADJUVANT THERAPY FOR RECTAL CANCER BY ANORECTAL MANOMETRY AND JORGE-WEXNER SCORE
- Staging rectal cancer: endoscopic ultrasound and pelvic MRI
- Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study